NCT04085653 2026-04-14
Managed Access Programs for BYL719, Alpelisib
Novartis
Available
Clinical Trials
16 trialsNCT06443944 2026-04-14
An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
CG Oncology, Inc.
Available
NCT01163383 2026-04-13
131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Children's Hospital of Philadelphia
Available
NCT05038631 2026-04-13
Managed Access Programs for LEE011, Ribociclib
Novartis
Available
NCT06877676 2026-04-13
Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use
Janssen Research & Development, LLC
Approved for marketing
NCT05776134 2026-04-08
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Gilead Sciences
Available
NCT06834074 2026-04-07
NVL-655-EAP
Nuvalent Inc.
Available
NCT06948955 2026-04-02
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.
Available
NCT05041036 2026-04-01
Individual Patient Compassionate Use of Nirogacestat
SpringWorks Therapeutics, Inc.
Available
NCT05100134 2026-04-01
Managed Access Programs for LDK378, Ceritinib
Novartis
No longer available
NCT07502716 2026-03-31
Compassionate Use of Ubamatamab
Regeneron Pharmaceuticals
Available
NCT06761976 2026-03-30
Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation
Bayer
Available
NCT05028166 2026-03-27
Individual Patient Compassionate Use of Mirdametinib
SpringWorks Therapeutics, Inc.
Available
NCT06810141 2026-03-27
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
ImmunityBio, Inc.
Available
NCT07497984 2026-03-27
ITM11 Expanded Access Program
ITM Solucin GmbH
Available
NCT04571229 2026-03-18
Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma
Memorial Sloan Kettering Cancer Center
Available